| Literature DB >> 28833674 |
Bryony L Elbert1, Alistair J M Farley1, Timothy W Gorman1, Tarn C Johnson1, Christophe Genicot2, Bénédicte Lallemand2, Patrick Pasau2, Jakub Flasz3, José L Castro3, Malcolm MacCoss4, Robert S Paton1, Christopher J Schofield1, Martin D Smith1, Michael C Willis1, Darren J Dixon1.
Abstract
Heteroaromatic nitriles are important compounds in drug discovery, both for their prevalence in the clinic and due to the diverse range of transformations they can undergo. As such, efficient and reliable methods to access them have the potential for far-reaching impact across synthetic chemistry and the biomedical sciences. Herein, we report an approach to heteroaromatic C-H cyanation through triflic anhydride activation, nucleophilic addition of cyanide, followed by elimination of trifluoromethanesulfinate to regenerate the cyanated heteroaromatic ring. This one-pot protocol is simple to perform, is applicable to a broad range of decorated 6-ring N-containing heterocycles, and has been shown to be suitable for late-stage functionalization of complex drug-like architectures.Entities:
Keywords: cyanation; heterocycles; late-stage functionalization; nitriles
Year: 2017 PMID: 28833674 PMCID: PMC5813275 DOI: 10.1002/chem.201703931
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236
Scheme 1(a) Nitrile‐containing drugs: bosutinib (1), tyrosine kinase inhibitor; topiroxostat (2), xanthine oxidase inhibitor; MIV‐150 (3) non‐nucleoside reverse transcriptase inhibitor. (b) Proposed three‐stage protocol for one‐pot C−H cyanation.
Selected reaction optimization data.[a]
|
| ||||||
|---|---|---|---|---|---|---|
| Entry |
|
|
| Solvent | Yield [%][b] | Ratio |
| 1 | −78 | 40 | 0 | CH2Cl2 | 30 | 53:47 |
| 2 | −78 | 40 | 3 | CH2Cl2 | 61 | 59:41 |
| 3 | 21 | 40 | 3 | CH2Cl2 | 75 | 61:39 |
| 4 | 21 | 110 | 3 | PhMe | 59 | 62:38 |
| 5 | 21 | 80 | 3 | DCE | 69 | 61:39 |
| 6 | 21 | 60 | 3 | CHCl3 | 80 | 61:39 |
| 7[d] | 21 | 60 | 3 | CHCl3 | 74 | 59:41 |
[a] Conditions: Tf2O (1.2 equiv) added to substrate (100 mg) in solvent (0.1 m) at T 1, stirred 1 h, then TMSCN (5.0 equiv) was added, warmed to T 2 for t 1. NMM (1.3 equiv) was added, stirred for 20−t 1 h before quenching with NaHCO3. Fully rearomatized in each case. [b] Isolated yield. [c] Determined following isolation by flash column chromatography. [d] Performed on 1 g scale.
Scheme 2Substrate scope. Conditions: 0.7 mmol scale, Tf2O (1.2 equiv), CHCl3 (0.1 m wrt substrate), 1 h, RT; then TMSCN (5.0 equiv), 3 h at 60 °C; then NMM (1.3 equiv), 17 h at 60 °C. Yields are of isolated materials. Isomeric ratio was determined from isolated amounts of purified material. For consistency, numbering of functionalized carbon refers to the starting material. [a]<0.7 mmol scale, see the Supporting Information for details.
Scheme 3Late‐stage cyanation of drug and natural‐product derivatives. Conditions: Tf2O (1.2 equiv), CHCl3 (0.1 m wrt substrate), 1 h, RT; then TMSCN (5.0 equiv), 3 h at 60 °C; then NMM (1.3 equiv), 17 h at 60 °C. Isomeric ratio was determined from amounts of purified material.
Figure 1Magnitude of computed atomic Fukui indices for N‐triflyl heterocycles, f (r) (green circles), correlate with the site of nucleophilic attack (blue/grey arrows). Results for several other substrates are shown in the Supporting Information.